Physician profile
Nabil Mansour
NPI 1295013241
$7,930.80
in general payments reported to CMS, 2019-2025
19 companies · $1,432 in 2025
The $1,432 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $16.42 · 2021: $55.67 · 2022: $1,212 · 2023: $1,062 · 2024: $3,973 · 2025: $1,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,766 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,925 · Travel and Lodging: $1,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,766.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,925.00 |
| Travel and Lodging | $1,776.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,075.92 | 2022-2025 | Gi Genius, Endoflip, Sharkcore |
| Abbvie INC. | $840.66 | 2019-2025 | |
| Boston Scientific Corporation | $562.79 | 2023-2025 | Orise, Wallflex Duodenal, Spyglass |
| Steris Corporation | $422.43 | 2022 | |
| 3-D Matrix, INC. | $248.98 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $142.58 | 2019-2025 | Entyvio |
| Fujifilm Healthcare Americas Corporation | $140.55 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.07 | 2019-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $80.23 | 2023 | Voquezna |
| Madrigal Pharmaceuticals | $62.36 | 2025 | Rezdiffra |
| Conmed Corporation | $59.42 | 2022 | |
| Endogastric Solutions, INC | $50.04 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $34.04 | 2024 | Dupixent |
| Janssen Biotech, INC. | $33.69 | 2025 | Tremfya |
| Alcresta Therapeutics, INC. | $25.00 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $18.44 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $16.42 | 2020 | |
| Shire North American Group INC | $15.14 | 2019 | |
| Mauna Kea Technologies, INC. | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabil Mansour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.